The single-dose Janssen Ad26.COV2.S COVID-19 vaccine elicited robust and persistent anti-spike IgG antibody responses in a 12-month Ugandan cohort DOI Creative Commons
Jennifer Serwanga,

Laban Kato,

Gerald Kevin Oluka

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: May 8, 2024

Introduction The study investigation examined the immune response to Janssen Ad26.COV2.S COVID-19 vaccine within a Ugandan cohort, specifically targeting antibodies directed against spike (S) and nucleocapsid (N) proteins. We aimed examine durability robustness of induced antibody while also assessing occurrences breakthrough infections previous anti-Spike seropositivity SARS-CoV-2. Methods included 319 specimens collected over 12 months from 60 vaccinees aged 18 64. Binding were quantified using validated ELISA method measure SARS-CoV-2-specific IgG, IgM, IgA levels S N Results results showed that baseline for S-IgG was high at 67%, increasing 98% by day 14 consistently stayed above 95% up months. However, S-IgM responses remained suboptimal. A raised S-IgA rate seen doubled 40% 86% just two weeks following initial dose, indicating sustained robust peripheral immunity. An increase in N-IgG nine post-vaccination suggested eight cases. Baseline cross-reactivity influenced spike-directed responses, with individuals harbouring showing notably higher responses. Discussion Robust long lasting infection-induced observed, significant implications regions where administering subsequent doses poses logistical challenges.

Language: Английский

Safety and Immunogenicity of a Modified Self-Amplifying Ribonucleic Acid (saRNA) Vaccine Encoding SARS-CoV-2 Spike Glycoprotein in SARS-CoV-2 Seronegative and Seropositive Ugandan Individuals DOI
Jonathan Kitonsa, Jennifer Serwanga, Andrew Abaasa

et al.

Published: Jan. 1, 2025

Language: Английский

Citations

0
The single-dose Janssen Ad26.COV2.S COVID-19 vaccine elicited robust and persistent anti-spike IgG antibody responses in a 12-month Ugandan cohort DOI Creative Commons
Jennifer Serwanga,

Laban Kato,

Gerald Kevin Oluka

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: May 8, 2024

Introduction The study investigation examined the immune response to Janssen Ad26.COV2.S COVID-19 vaccine within a Ugandan cohort, specifically targeting antibodies directed against spike (S) and nucleocapsid (N) proteins. We aimed examine durability robustness of induced antibody while also assessing occurrences breakthrough infections previous anti-Spike seropositivity SARS-CoV-2. Methods included 319 specimens collected over 12 months from 60 vaccinees aged 18 64. Binding were quantified using validated ELISA method measure SARS-CoV-2-specific IgG, IgM, IgA levels S N Results results showed that baseline for S-IgG was high at 67%, increasing 98% by day 14 consistently stayed above 95% up months. However, S-IgM responses remained suboptimal. A raised S-IgA rate seen doubled 40% 86% just two weeks following initial dose, indicating sustained robust peripheral immunity. An increase in N-IgG nine post-vaccination suggested eight cases. Baseline cross-reactivity influenced spike-directed responses, with individuals harbouring showing notably higher responses. Discussion Robust long lasting infection-induced observed, significant implications regions where administering subsequent doses poses logistical challenges.

Language: Английский

Citations

0